🎉 M&A multiples are live!
Check it out!

Nanjing King-Friend Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nanjing King-Friend and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Nanjing King-Friend Overview

About Nanjing King-Friend

Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.


Founded

2000

HQ

China
Employees

n/a

Website

nkf-pharma.com

Financials

LTM Revenue $619M

LTM EBITDA $157M

EV

$2.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nanjing King-Friend Financials

As of November 2025, Nanjing King-Friend reported last 12-month revenue of $619M and EBITDA of $157M.

In the same period, Nanjing King-Friend generated $258M in LTM gross profit and $109M in net income.

See Nanjing King-Friend valuation multiples based on analyst estimates

Nanjing King-Friend P&L

In the most recent fiscal year, Nanjing King-Friend reported revenue of $554M and EBITDA of $176M.

Nanjing King-Friend expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nanjing King-Friend valuation multiples based on analyst estimates
LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $619M XXX $554M XXX XXX XXX
Gross Profit $258M XXX $240M XXX XXX XXX
Gross Margin 42% XXX 43% XXX XXX XXX
EBITDA $157M XXX $176M XXX XXX XXX
EBITDA Margin 25% XXX 32% XXX XXX XXX
EBIT $130M XXX $129M XXX XXX XXX
EBIT Margin 21% XXX 23% XXX XXX XXX
Net Profit $109M XXX $117M XXX XXX XXX
Net Margin 18% XXX 21% XXX XXX XXX
Net Debt XXX XXX $146M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nanjing King-Friend Stock Performance

Nanjing King-Friend has current market cap of CNY 15.6B (or $2.2B), and EV of CNY 15.4B (or $2.2B).

Market Cap Evolution

Nanjing King-Friend Stock Data

As of December 3, 2025, Nanjing King-Friend's stock price is CNY 10 (or $1).

See Nanjing King-Friend trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.2B $2.2B XXX XXX XXX XXX $0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Nanjing King-Friend Valuation Multiples

Nanjing King-Friend's trades at 3.9x EV/Revenue multiple, and 12.4x EV/EBITDA.

See valuation multiples for Nanjing King-Friend and 15K+ public comps

Nanjing King-Friend Financial Valuation Multiples

As of December 3, 2025, Nanjing King-Friend has market cap of $2.2B and EV of $2.2B.

Equity research analysts estimate Nanjing King-Friend's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Nanjing King-Friend has a P/E ratio of 20.3x.

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $2.2B XXX $2.2B XXX XXX XXX
EV (current) $2.2B XXX $2.2B XXX XXX XXX
EV/Revenue 3.5x XXX 3.9x XXX XXX XXX
EV/EBITDA 13.8x XXX 12.4x XXX XXX XXX
EV/EBIT 16.7x XXX 16.8x XXX XXX XXX
EV/Gross Profit 8.4x XXX n/a XXX XXX XXX
P/E 20.3x XXX 18.9x XXX XXX XXX
EV/FCF n/a XXX 15.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nanjing King-Friend Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Nanjing King-Friend Margins & Growth Rates

Nanjing King-Friend's last 12 month revenue growth is 21%

Nanjing King-Friend's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Nanjing King-Friend's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Nanjing King-Friend's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Nanjing King-Friend and other 15K+ public comps

Nanjing King-Friend Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 21% XXX 17% XXX XXX XXX
EBITDA Margin 25% XXX 32% XXX XXX XXX
EBITDA Growth 30% XXX n/a XXX XXX XXX
Rule of 40 19% XXX 52% XXX XXX XXX
Bessemer Rule of X XXX XXX 77% XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX n/a XXX XXX XXX
S&M Expenses to Revenue XXX XXX 7% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 8% XXX XXX XXX
Opex to Revenue XXX XXX 20% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nanjing King-Friend Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nanjing King-Friend M&A and Investment Activity

Nanjing King-Friend acquired  XXX companies to date.

Last acquisition by Nanjing King-Friend was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nanjing King-Friend acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nanjing King-Friend

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Nanjing King-Friend

When was Nanjing King-Friend founded? Nanjing King-Friend was founded in 2000.
Where is Nanjing King-Friend headquartered? Nanjing King-Friend is headquartered in China.
Is Nanjing King-Friend publicy listed? Yes, Nanjing King-Friend is a public company listed on SHG.
What is the stock symbol of Nanjing King-Friend? Nanjing King-Friend trades under 603707 ticker.
When did Nanjing King-Friend go public? Nanjing King-Friend went public in 2017.
Who are competitors of Nanjing King-Friend? Similar companies to Nanjing King-Friend include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Nanjing King-Friend? Nanjing King-Friend's current market cap is $2.2B
What is the current revenue of Nanjing King-Friend? Nanjing King-Friend's last 12 months revenue is $619M.
What is the current revenue growth of Nanjing King-Friend? Nanjing King-Friend revenue growth (NTM/LTM) is 21%.
What is the current EV/Revenue multiple of Nanjing King-Friend? Current revenue multiple of Nanjing King-Friend is 3.5x.
Is Nanjing King-Friend profitable? Yes, Nanjing King-Friend is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Nanjing King-Friend? Nanjing King-Friend's last 12 months EBITDA is $157M.
What is Nanjing King-Friend's EBITDA margin? Nanjing King-Friend's last 12 months EBITDA margin is 25%.
What is the current EV/EBITDA multiple of Nanjing King-Friend? Current EBITDA multiple of Nanjing King-Friend is 13.8x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.